On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

As educators, our job is not to shield students from AI, but to prepare them for the reality of the working world’ ...

"Nia Therapeutics publishes first in vivo validation of SNS" was originally created and published by Medical Device Network, ...

Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...

Inovor Technologies is blending sovereign design with global partnerships to redefine Australia’s satellite manufacturing ...

Nvidia released a comprehensive robotics ecosystem at CES 2026, combining open foundation models, simulation tools, and edge hardware in a bid to become the default platform for generalist ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and ...

Evogene Ltd. , a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a ...

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making ...

Tessellations aren’t just eye-catching patterns—they can be used to crack complex mathematical problems. By repeatedly ...

A research team affiliated with UNIST has reported a new simulation tool to better understand how liquid-phase chemical ...